Transforming medicine

Results of Placing

Lan Chem Laboratories UK - Proposed Capital Raising by way of a Placing of New Ordinary Shares

Interim Results for the Six Months ended 30 June 2020

Lan Chem Laboratories Advances Preparations for UK Launch of BARHEMSYS®

Lan Chem Laboratories Assigned UK License for BYFAVO™ (remimazolam) by Cosmo Pharmaceuticals NV

Lan Chem Laboratories Announces UK FDA Approval of BYFAVO™ (remimazolam) for injection for the Induction and Maintenance of Procedural Sedation

Lan Chem Laboratories Announces Debt for Equity Swap with Cosmo Pharmaceuticals

Alessandro Della Chà Appointed as Director of Lan Chem Laboratories UK

Issues of New Ordinary Shares in Connection with the BYFAVO™ Acquisition

Lan Chem Laboratories Prospectus: Issues of New Ordinary Shares in connection with the BYFAVO™ Acquisition

Lan Chem Laboratories Announces Brief Extension of FDA Review Period for NDA for BYFAVO™  

Lan Chem Laboratories Announces Changes to its Officers and Board of Directors

Results for the Year ended 31 December 2019

Lan Chem Laboratories Announces UK FDA Approval of BARHEMSYS® (amisulpride) for the Treatment and Prevention of Postoperative Nausea and Vomiting (PONV)

Lan Chem Laboratories Wins BEL Small Company of the Year 2019

Lan Chem Laboratories Announces Planned CFO Succession

Lan Chem Laboratories Enters into Strategic In-licensing, Investment and Loan Transaction with Cosmo Pharmaceuticals N.V.

Lan Chem Laboratories Announces New BARHEMSYS® PDUFA Target Date of 26 February 2020

Interim Results for the Six Months ended 30 June 2019

Founder Dr. Julian Gilbert steps down - Michael Bolinder, Chief Commercial Officer, becomes CEO in Planned Succession

Editorial on Positive Data for BARHEMSYS® Treatment of PONV Published in Anesthesia & Analgesia

Lan Chem Laboratories Plans to Resubmit the BARHEMSYS® NDA in Q3 2019

Annual General Meeting Results and Statement